8-K: Canopy Growth to Acquire MTL Cannabis in C$125M Deal

Canopy Growth Corporation announced a definitive agreement to acquire MTL Cannabis Corp. for approximately C$125 million, aiming to create Canada's leading medical cannabis business and enhance global supply.

Summary

• Canopy Growth Corporation will acquire all issued and outstanding common shares of MTL Cannabis Corp. for approximately C$125 million on a fully-diluted equity basis, or C$179 million on an enterprise value basis.
• MTL shareholders will receive 0.32 of a Canopy Growth common share and C$0.144 in cash for each MTL share, representing a 45% premium to MTL's 20-day volume weighted average trading price on the CSE as of December 12, 2025.
• The transaction is expected to generate approximately C$10 million in annualized run-rate synergies within 18 months, primarily from operating efficiencies and corporate integration.
• MTL Cannabis reported C$84 million in net revenue, 51% gross margin before fair value adjustments, and C$11 million in operating cash flow for the trailing twelve-month period ended September 30, 2025.
• MTL Cannabis's interim financial results for the six months ended September 30, 2025, show a net loss of C$(8,366,496) compared to a net income of C$3,452,091 in the prior year period.
• Operating income for MTL Cannabis decreased significantly to C$2,108,011 for the six months ended September 30, 2025, from C$9,053,900 in the same period of 2024.
• MTL Cannabis's cash balance decreased to C$2,954,224 as of September 30, 2025, from C$5,680,958 as of March 31, 2025.
• MTL Cannabis secured a new credit agreement on July 30, 2025, with a Canadian Schedule 1 Bank, drawing C$19,447,982 across various facilities to finance capital expenditures, working capital, and refinance existing debt.
• All convertible debentures of MTL Cannabis, totaling C$7,583,236 as of March 31, 2025, were fully repaid on July 31, 2025.
• A private placement by MTL Cannabis closed on September 19, 2025, raising C$2,046,199 in gross proceeds (C$1,670,835 net cash).
• MTL's founders, Richard and Michel Clement, will enter into 18-month consulting agreements with Canopy Growth, including C$2,000,000 in performance stock units each.
• Michael Perron, MTL's CEO, will be appointed Chief Operating Officer of Canopy Growth, with a base salary of C$450,000 and equity awards.

Sentiment

Score: 8

Explanation: The filing announces a strategic acquisition with a significant premium for the target company's shareholders and clear benefits for the acquirer, including synergies, market leadership, and management talent. While the target's recent standalone financials show a loss, the acquisition is framed as accretive and a positive step for the combined entity's future profitability and market position. The retention of key management and strong shareholder support further bolster positive sentiment.

Positives

• The transaction offers MTL shareholders a significant 45% premium over the recent trading price, providing immediate value.
• MTL shareholders will gain enhanced liquidity through Canopy Growth shares, which have an average daily trading volume exceeding C$35 million.
• The acquisition is expected to generate C$10 million in annualized run-rate synergies within 18 months, enhancing the combined entity's financial performance.
• Canopy Growth will leverage MTL's proven cultivation expertise and high-quality flower supply to strengthen its position in Canadian and international medical cannabis markets, particularly in Europe.
• The acquisition bolsters Canopy Growth's presence in Quebec, Canada's second-largest cannabis market, with two cultivation facilities and established brands like MTL and R'belle.
• MTL's strong brand portfolio, including #1 national market share in upper mainstream flower and #4 in upper mainstream pre-roll joints, will improve Canopy Growth's overall market ranking to #7 in total adult-use cannabis.
• The retention of MTL's core management team, including its founders and CEO, is expected to strengthen Canopy Growth's leadership and operational capabilities.
• MTL Cannabis reported positive operating cash flow of C$11 million for the trailing twelve-month period ended September 30, 2025, contributing to the combined entity's cash generation.

Negatives

• MTL Cannabis reported a significant net loss of C$(8,366,496) for the six months ended September 30, 2025, a substantial decline from a net income of C$3,452,091 in the prior year period.
• Gross profit for MTL Cannabis decreased by approximately 25% to C$18,723,806 for the six months ended September 30, 2025, from C$24,889,321 in the same period of 2024.
• Operating income for MTL Cannabis fell sharply to C$2,108,011 for the six months ended September 30, 2025, compared to C$9,053,900 in the prior year period.
• Finance expenses for MTL Cannabis more than doubled to C$10,007,929 for the six months ended September 30, 2025, largely due to C$6,875,343 in warrants issued.
• MTL Cannabis's cash balance declined by over 48% from C$5,680,958 at March 31, 2025, to C$2,954,224 at September 30, 2025, indicating significant cash burn.
• The company's total liabilities increased to C$66,540,063 as of September 30, 2025, from C$64,393,422 as of March 31, 2025, driven by new borrowings.

Risks

• The Arrangement is subject to various conditions, including approval by the Supreme Court of British Columbia, Competition Act (Canada) approvals, and MTL shareholder approval, which may not be obtained.
• MTL shareholders exercising Dissent Rights exceeding 10% of outstanding shares could impact the transaction.
• The integration of MTL's businesses into Canopy Growth's operations may face challenges, potentially affecting the realization of anticipated synergies and operational efficiencies.
• The dilutive impact of issuing Canopy Growth Shares as consideration and future resales by MTL shareholders could negatively affect Canopy Growth's stock price.
• The cannabis industry is subject to significant regulatory and market changes, which could impact the combined entity's performance.
• The MC Shareholder Consideration is subject to an 18-month transfer restriction, which could affect liquidity for those specific shareholders.

Future Outlook

The combined entity is expected to achieve a leading position in Canada's medical cannabis market and enhance its capacity to serve growing international demand, particularly in Europe. The transaction is anticipated to be materially accretive to Canopy Growth's overall financial performance and support its goal of achieving positive adjusted EBITDA, driven by C$10 million in annualized synergies and leveraging MTL's profitable business and cultivation expertise. Canopy Growth plans to expand MTL's product distribution nationally and integrate MTL's production assets into its supply chain.

Management Comments

• Luc Mongeau, CEO of Canopy Growth, stated: "MTL brings skilled operators, strong brands, and a profitable business that will strengthen our leadership in Canada's medical market and deepens our presence in key Canadian adult-use markets, including Quebec. Their cultivation expertise, combined with our national scale, positions us to improve product quality, expand supply, and accelerate our path to profitable growth. Together, we're building a stronger, more competitive Canadian business for the long term."
• Richard Clément, Co-Founder and Chief Cultivation Officer of MTL Cannabis, commented: "MTL was built on the idea that high-quality flower, grown with care and consistency, will always earn the trust of consumers and patients. Joining Canopy Growth gives us the platform to bring that philosophy to more Canadians. Our respective portfolios are highly complementary, and we see a strong opportunity to expand MTL's reach through Canopy Growth's national distribution and retail relationships. We're incredibly proud of what our team has built and look forward to working with Canopy Growth to continue elevating Canadian cannabis."

Industry Context

This acquisition positions Canopy Growth to become the leading medical cannabis provider in Canada by integrating MTL's patient network, clinics, and online medical channel. It also strengthens Canopy Growth's footprint in Quebec, Canada's second-largest cannabis market, and improves its national market ranking in adult-use product categories. The move reflects a trend towards consolidation and strategic asset acquisition in the Canadian cannabis industry, focusing on operational excellence, brand strength, and expanding international export capabilities, particularly to the European medical cannabis market.

Comparison to Industry Standards

• MTL Cannabis holds the #1 national market share in upper mainstream flower, as recognized in a 2024 Brightfield Study.
• MTL Cannabis holds the #4 national market share in upper mainstream pre-roll joints (PRJ).
• The combined entity is expected to achieve the #7 position in total adult-use cannabis market share.
• MTL Cannabis was recognized as Canada's #1 budtender-recommended brand in a 2024 Brightfield Study, indicating strong consumer and industry perception of product quality.
• MTL Cannabis received the 'Brand of the Year' award at the 2024 Grow Up Conference in Toronto, further validating its market standing and product quality.

Management Changes

Corporate Governance

Related Party Transactions

• MTL Cannabis had notes payable to certain related parties, bearing 17% interest per annum, with repayment deferred until August 30, 2028, subject to lender demand.
• New promissory notes totaling C$4,624,716 were issued to the Chief Cultivation Officer and Chief Operating Officer to defer repayment of a C$5,000,000 provision owed to pre-RTO MTL Cannabis shareholders.
• MTL Cannabis purchased C$1,373,090 of equipment and services from companies owned by key management personnel during the six months ended September 30, 2025.
• MTL Cannabis made rental and lease payments totaling C$1,345,494 to related parties during the six months ended September 30, 2025.
• The lease agreements for MTL's head office and production facility were modified on July 29, 2025, extending the non-cancellable period and increasing right-of-use assets, with the leased premises owned by a company controlled by the Chief Cultivation Officer and Chief Operating Officer.

Stakeholder Impact

• **Shareholders (MTL Cannabis):** Receive a significant 45% premium and enhanced liquidity through Canopy Growth shares, along with exposure to a broader global cannabis market.
• **Shareholders (Canopy Growth):** Expected to benefit from strategic market leadership, operational synergies, and an accelerated path to positive adjusted EBITDA, though there is potential for dilution from share issuance.
• **Employees (MTL Cannabis):** Core management team members are being retained with new roles and compensation packages at Canopy Growth, indicating job security for key personnel.
• **Customers/Patients:** The combined entity aims to strengthen its position as a leading medical cannabis provider in Canada and enhance product quality and supply for both medical and adult-use consumers.
• **Creditors:** Existing debt of MTL Cannabis is being settled or refinanced as part of the transaction, with new credit facilities secured, potentially altering the credit risk profile.

Next Steps

• MTL Cannabis will convene a special shareholder meeting by February 17, 2026, to vote on the Arrangement Resolution.
• The transaction requires approval from the Supreme Court of British Columbia, Competition Act (Canada) approvals, and Toronto Stock Exchange listing approval.
• The closing of the transaction is expected to occur by the end of February 2026.
• Canopy Growth will integrate MTL's cultivation and post-harvest assets into its supply chain.
• Canopy Growth will work to expand the distribution of MTL's flower, pre-roll, and hash product portfolio in British Columbia, Alberta, and Ontario.

Key Dates

Recommendation

The acquisition of MTL Cannabis by Canopy Growth is a highly strategic move that is expected to be materially accretive to Canopy Growth's financial performance. The 45% premium offered to MTL shareholders is attractive, and the integration of MTL's profitable operations, strong brands (including #1 budtender-recommended flower), and cultivation expertise will significantly enhance Canopy Growth's market position in Canada's medical and adult-use sectors, particularly in Quebec. The projected C$10 million in annualized synergies, combined with Canopy Growth's existing expense reductions, provides a clear path to positive adjusted EBITDA. The retention of key MTL management further strengthens the operational outlook. For investors, this transaction represents a compelling opportunity for Canopy Growth to consolidate its leadership, improve profitability, and expand its global reach, making it a strong buy.

Keywords

Cannabis, Acquisition, Merger, Canopy Growth, MTL Cannabis, Medical Cannabis, Adult-Use Cannabis, Quebec, Cultivation, Financial Reporting, SEC Filing, Synergies, Market Share, Corporate Governance